Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

On the top-line, Lilly’s revenue grew by 45%, a brisk pace that was in line with expectations. Earnings more than doubled, beating analyst estimates by 6%. Mounjaro and Zepbound, the company’s ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Lilly's growth was led by its GLP-1 drugs. For the quarter, revenue for Mounjaro soared 60% year over year to $3.5 billion, while revenue for Zepbound surged from $175.8 million to $1.9 billion.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...